Compare SVRE & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.4M |
| IPO Year | N/A | 2021 |
| Metric | SVRE | CMND |
|---|---|---|
| Price | $3.05 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.0K | 71.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $453.30 | N/A |
| Revenue Next Year | $106.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.07 |
| 52 Week High | $5.69 | $3.25 |
| Indicator | SVRE | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 29.02 |
| Support Level | $1.99 | $0.08 |
| Resistance Level | $3.15 | $1.07 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 83.79 | 17.72 |
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.